Lipocine (LPCN) Revenue (2018 - 2025)

Lipocine (LPCN) has reported Revenue for 7 consecutive years, with $114574.0 the latest figure, recorded in Q3 2025.

• For the quarter ending Q3 2025, Revenue changed N/A year-over-year to $114574.0; the trailing twelve-month figure through Sep 2025 stood at $4.3 million (down 42.29% YoY), and the FY2024 full-year result was $11.2 million, up 292.8% from the prior year.
• Revenue declined to $114574.0 in Q3 2025 per LPCN's latest filing, from $622849.0 in the prior quarter.
• Across five years, Revenue topped out at $16.1 million in Q4 2021 and bottomed at -$216188.0 in Q4 2023.
• Historically, Revenue has averaged $2.6 million across 5 years, with a median of $307287.0 in 2022.
• The sharpest annual moves came in 2024 and 2025: Revenue soared 13751.93% in 2024, then sank 98.77% in 2025.
• Over 5 years, Revenue stood at $16.1 million in 2021, then slumped by 96.89% to $500000.0 in 2022, then tumbled by 143.24% to -$216188.0 in 2023, then jumped by 1714.99% to $3.5 million in 2024, then plunged by 96.72% to $114574.0 in 2025.
• According to Business Quant data, Revenue over the past three periods registered $114574.0, $622849.0, and $93864.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.